Recent analyst revisions have brought Pacific Biosciences of California into focus as price targets have shifted into a tighter band around the US$2 to US$2.70 range. These changes reflect updated views from both more optimistic and more cautious analysts who are reassessing the stock as new earnings previews and sector comparisons come through. As you read on, you will see how these moving targets fit into the broader story and how to track the evolving narrative around Pacific Biosciences of California.
What Wall Street Has Been Saying
🐂 Bullish Takeaways
-
Stephens raised its PacBio price target to US$2.50 from US$1.50 and kept an Overweight rating, indicating a more constructive view on how Pacific Biosciences of California might execute against upcoming diagnostics and medical technologies sector expectations.
-
Barclays increased its PacBio price target to US$2 from US$1.25 while maintaining an Underweight rating, which still signals caution but also shows that the firm sees room for some improvement in the valuation framework it applies to the stock.
🐻 Bearish Takeaways
-
UBS most recently lowered its PacBio price target to US$2.70 from US$3.05 and kept a Neutral rating, highlighting ongoing questions around how Pacific Biosciences of California will deliver on growth ambitions relative to prior expectations.
-
UBS had previously assumed coverage of PacBio with a Neutral rating and a US$1.35 price target, and the firm framed life science tools as tied to broad economic activity, which can limit how much upside some investors may be willing to assign to the stock in the near term.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there’s more to the story. Head to the Simply Wall St Community to discover more perspectives!
We’ve flagged 3 risks for Pacific Biosciences of California. See which could impact your investment.
How This Changes the Fair Value For Pacific Biosciences of California
-
Fair value updated from US$2.54 to US$2.78 in the latest assessment.
-
Revenue growth assumption updated from 12.25% to 12.66% for Pacific Biosciences of California.
-
Net profit margin revised from 16.23% to 14.57% in the updated profitability outlook.
-
Future P/E multiple updated from 31.24x to 38.96x in the current modeling.
-
Discount rate adjusted from 9.81% to 10.53% as the required return input in the model.